7.85
-0.32 (-3.92%)
| Penutupan Terdahulu | 8.17 |
| Buka | 7.90 |
| Jumlah Dagangan | 1,290,254 |
| Purata Dagangan (3B) | 943,264 |
| Modal Pasaran | 830,851,840 |
| Harga / Jualan (P/S) | 3.12 |
| Harga / Buku (P/B) | 1.95 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Keuntungan | -109.69% |
| Margin Operasi (TTM) | -396.15% |
| EPS Cair (TTM) | -3.14 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.78% |
| Nisbah Semasa (MRQ) | 4.50 |
| Aliran Tunai Operasi (OCF TTM) | -170.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -41.25 M |
| Pulangan Atas Aset (ROA TTM) | -17.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Arcus Biosciences, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.63 |
|
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.52% |
| % Dimiliki oleh Institusi | 83.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gilead Sciences, Inc. | 31 Dec 2024 | 30,061,124 |
| Invus Financial Advisors, Llc | 30 Jun 2024 | 1,612,077 |
| Siren, L.L.C. | 31 Dec 2024 | 1,612,077 |
| Boxer Capital, Llc | 30 Sep 2024 | 1,602,200 |
| Boxer Capital Management, Llc | 31 Dec 2024 | 1,602,200 |
| Parkman Healthcare Partners Llc | 31 Dec 2024 | 1,273,789 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 26.00 (Wells Fargo, 231.21%) | Beli |
| Median | 18.00 (129.30%) | |
| Rendah | 13.00 (Goldman Sachs, 65.61%) | Pegang |
| Purata | 18.75 (138.85%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 8.23 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 09 May 2025 | 22.00 (180.25%) | Beli | 8.28 |
| Goldman Sachs | 08 May 2025 | 13.00 (65.61%) | Pegang | 8.53 |
| Wells Fargo | 07 May 2025 | 26.00 (231.21%) | Beli | 8.01 |
| Barclays | 23 Apr 2025 | 14.00 (78.34%) | Beli | 8.11 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 May 2025 | Pengumuman | Arcus Biosciences Announces New Employment Inducement Grants |
| 09 May 2025 | Pengumuman | Arcus Biosciences Announces New Employment Inducement Grants |
| 06 May 2025 | Pengumuman | Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update |
| 24 Apr 2025 | Pengumuman | Arcus Biosciences Announces New Employment Inducement Grants |
| 23 Apr 2025 | Pengumuman | Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting |
| 22 Apr 2025 | Pengumuman | Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update |
| 09 Apr 2025 | Pengumuman | Arcus Biosciences Announces New Employment Inducement Grants |
| 25 Mar 2025 | Pengumuman | Arcus Biosciences Announces New Employment Inducement Grants |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |